OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

OmniaBio Inc. announced the opening of a new North American cell and gene therapy manufacturing and artificial intelligence center of excellence, which is now Canada’s largest contract development and manufacturing organization facility dedicated to CGT. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at the Ohio State University Comprehensive Cancer Center is using artificial intelligence to devise new ways of predicting which patients will develop an aggressive and difficult-to-detect form of breast cancer called lobular cancer, which represents one in every 10 breast cancers diagnosed in the United States.

Cell and gene therapies are steadily becoming more available to patients, but are still facing systemic hurdles slowing widespread adoption, according to the second annual 2025 “Cell and Gene Therapy Report: Advancing the Future of Medicine,” published by InspiroGene by McKesson. The report draws on new insights from research with physicians and payers, an updated...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login